Savolitinib plus osimertinib received breakthrough therapy designation in China for pretreated, locally advanced or metastatic EGFR-positive NSCLC with MET amplification.
PURPOSETo assess the efficacy and safety of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) in treating recurrent small hepatocellular carcinoma (HCC).METHODSIn this trial, patients…
Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.
Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.
SURVIVOR launches a new chapter when the Emmy Award-winning series returns on Wednesdays. Stranded in the beautiful islands of Fiji, these 18 determined new castaways…
Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.
A real-world study sought to measure survival outcomes against the results of a pivotal clinical trial on the effectiveness of durvalumab plus chemotherapy.
Dr. Toni K. Choueiri shares how hard work and focus keeps him from getting discouraged or giving up when times get hard.
Evan Y. Yu, MD, discusses how the goals of therapy for a patient with newly- diagnosed metastatic hormone-sensitive prostate cancer are to control disease progression,…
China has made significant strides in drug development over the past two decades, transitioning from being a producer of generic drugs to a…
